YSP Southeast Asia Holding Bhd
YSP Southeast Asia Holding Bhd maintains a strong liquidity position, with a current ratio of 5.27 and cash and equivalents amounting to MYR 148.1 million, which is significantly higher than the industry median. The company's debt-to-equity ratio of 0.12 indicates a conservative capital structure, with long-term debt at MYR 50.8 million compared to total equity of MYR 417.9 million. Profitability metrics show a return on equity (ROE) of 5.99% and a return on assets (ROA) of 4.63%, which are in line with the industry's preferred metrics. The company's operating income of MYR 38.2 million and net income of MYR 25.0 million reflect a healthy margin, although gross profit of MYR 161.1 million suggests room for improvement in cost management. The company's revenue is distributed across three segments: Manufacturing, Trading, and Investment Holding. The Trading segment is the largest contributor, with a significant portion of revenue derived from the ASEAN region. The company's geographic exposure is concentrated in ASEAN, the Middle East, Africa, Australia, and New Zealand, with no significant diversification beyond these regions. Looking ahead, the company is projected to maintain a stable growth trajectory, with revenue expected to remain consistent in the current fiscal year and potentially increase in the next fiscal year. The company's capital expenditure of MYR -3.5 million indicates a focus on maintaining rather than expanding its current operations. Risk factors for the company are currently low, with no immediate liquidity or dilution flags detected. The company's low debt levels and strong cash reserves mitigate financial risk. However, the company's reliance on the pharmaceutical sector exposes it to regulatory and market volatility, which could impact future performance. Recent events, including filings and transcripts, have not indicated any significant changes in the company's operations or strategic direction. The company's ESG governance score of 68.8 and social score of 43.0 suggest a moderate level of commitment to environmental, social, and governance (ESG) practices.
Business. YSP Southeast Asia Holding Bhd is a Malaysia-based healthcare company engaged in the trading and manufacturing of pharmaceutical products, particularly generic drugs, and operates in the ASEAN, Middle East, Africa, Australia, and New Zealand markets.
Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.
- YSP Southeast Asia Holding Bhd has a strong liquidity position with a current ratio of 5.27 and significant cash reserves.
- The company's conservative capital structure, with a debt-to-equity ratio of 0.12, reduces financial risk.
- Profitability metrics, including ROE of 5.99% and ROA of 4.63%, are in line with industry standards.
- The company's revenue is concentrated in the Trading segment and the ASEAN region, which may limit diversification benefits.
- The company is projected to maintain stable growth with no significant capital expenditure planned.
- ESG governance practices are moderate, with a governance score of 68.8 and a social score of 43.0.
- --
- ## RATIONALES
- No immediate filing-based liquidity or dilution flags were detected.